Minimal Side Effects : Most patients experience only temporary redness and mild swelling
[7] [1] Patients with pre-existing renal impairment require careful monitoring of kidney function and hydration status
If dizziness persists despite appropriate management strategies, further investigation may be warranted to exclude other causes unrelated to the medication itself
A 0.3 mL, 31G, 5/16 inch syringe is not the same product as a 1 mL, 29G, 1/2 inch syringe
En moyenne, il faut prvoir 4 8 traitements selon les rsultats souhaits
However, it: Only results in modest weight loss (~5-7% body weight) Can cause gastrointestinal distress (diarrhea, nausea) Works best for those with insulin resistance rather than general obesity How GLP-1 and GIP Medications Offer Superior Weight Loss GLP-1 (Glucagon-Like Peptide-1) and GIP (Gastric Inhibitory Polypeptide) receptor agonists represent a new era in obesity treatment , working through multiple mechanisms to promote substantial and sustainable weight loss : Enhanced Appetite Suppression and Fullness GLP-1/GIP medications mimic natural gut hormones that regulate hunger and satiety, leading to: Significantly reduced appetite and cravings Longer-lasting fullness after meals No stimulant effects or addiction potential More Effective Weight Loss Compared to older medications, GLP-1 and GIP drugs produce greater and sustained weight loss : Tirzepatide (Mounjaro/Zepbound): 20-25% total body weight loss Semaglutide (Ozempic/Wegovy): 15-20% total body weight loss Phentermine & Topamax (Qsymia): 5-10% weight loss Metformin: 5-7% weight loss Long-Term Safety and Cardiometabolic Benefits Unlike Phentermine, which is only approved for short-term use , GLP-1/GIP medications are safe for long-term weight management
